222 related articles for article (PubMed ID: 33376148)
1. The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis.
Sun R; Kong B; Yang N; Cao B; Feng D; Yu X; Ge C; Feng S; Fei F; Huang J; Lu Z; Xie Y; Yang CS; Guo GL; Wang G; Aa J
Drug Metab Dispos; 2021 Mar; 49(3):276-286. PubMed ID: 33376148
[TBL] [Abstract][Full Text] [Related]
2. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
3. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis.
Xia X; Yan J; Shen Y; Tang K; Yin J; Zhang Y; Yang D; Liang H; Ye J; Weng J
PLoS One; 2011 Feb; 6(2):e16556. PubMed ID: 21304897
[TBL] [Abstract][Full Text] [Related]
4. An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.
Xie C; Jiang C; Shi J; Gao X; Sun D; Sun L; Wang T; Takahashi S; Anitha M; Krausz KW; Patterson AD; Gonzalez FJ
Diabetes; 2017 Mar; 66(3):613-626. PubMed ID: 28223344
[TBL] [Abstract][Full Text] [Related]
5. Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway.
Wei S; Zhang M; Yu Y; Lan X; Yao F; Yan X; Chen L; Hatch GM
PLoS One; 2016; 11(3):e0152097. PubMed ID: 27011261
[TBL] [Abstract][Full Text] [Related]
6. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.
Tian Y; Cai J; Gui W; Nichols RG; Koo I; Zhang J; Anitha M; Patterson AD
Drug Metab Dispos; 2019 Feb; 47(2):86-93. PubMed ID: 30409838
[TBL] [Abstract][Full Text] [Related]
7. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Jiang SJ; Dong H; Li JB; Xu LJ; Zou X; Wang KF; Lu FE; Yi P
World J Gastroenterol; 2015 Jul; 21(25):7777-85. PubMed ID: 26167077
[TBL] [Abstract][Full Text] [Related]
8. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition.
Renga B; Mencarelli A; D'Amore C; Cipriani S; Baldelli F; Zampella A; Distrutti E; Fiorucci S
FASEB J; 2012 Jul; 26(7):3021-31. PubMed ID: 22447981
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of cytokine signalling-2 controls hepatic gluconeogenesis and hyperglycemia by modulating JAK2/STAT5 signalling pathway.
Zhang X; Zhuang Y; Qin T; Chang M; Ji X; Wang N; Zhang Z; Zhou H; Wang Q; Li JZ
Metabolism; 2021 Sep; 122():154823. PubMed ID: 34197875
[TBL] [Abstract][Full Text] [Related]
11. Sodium meta-arsenite ameliorates hyperglycemia in obese diabetic db/db mice by inhibition of hepatic gluconeogenesis.
Lee YS; Lee EK; Oh HH; Choi CS; Kim S; Jun HS
J Diabetes Res; 2014; 2014():961732. PubMed ID: 25610880
[TBL] [Abstract][Full Text] [Related]
12. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
13. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis.
Zhang M; Lv X; Li J; Meng Z; Wang Q; Chang W; Li W; Chen L; Liu Y
Mol Cell Endocrinol; 2012 Nov; 363(1-2):122-30. PubMed ID: 22922125
[TBL] [Abstract][Full Text] [Related]
14. Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.
Dou Y; Huang R; Li Q; Liu Y; Li Y; Chen H; Ai G; Xie J; Zeng H; Chen J; Luo C; Su Z
Biomed Pharmacother; 2021 May; 137():111312. PubMed ID: 33524788
[TBL] [Abstract][Full Text] [Related]
15. Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice.
Zhong Y; Jin J; Liu P; Song Y; Zhang H; Sheng L; Zhou H; Jiang B
Oxid Med Cell Longev; 2020; 2020():6210526. PubMed ID: 31976031
[TBL] [Abstract][Full Text] [Related]
16. The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis.
Ploton M; Mazuy C; Gheeraert C; Dubois V; Berthier A; Dubois-Chevalier J; Maréchal X; Bantubungi K; Diemer H; Cianférani S; Strub JM; Helleboid-Chapman A; Eeckhoute J; Staels B; Lefebvre P
J Hepatol; 2018 Nov; 69(5):1099-1109. PubMed ID: 29981427
[TBL] [Abstract][Full Text] [Related]
17. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
18. In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine.
Yang N; Sun RB; Chen XL; Zhen L; Ge C; Zhao YQ; He J; Geng JL; Guo JH; Yu XY; Fei F; Feng SQ; Zhu XX; Wang HB; Fu FH; Aa JY; Wang GJ
Acta Pharmacol Sin; 2017 Mar; 38(3):351-361. PubMed ID: 28042874
[TBL] [Abstract][Full Text] [Related]
19. Dose-response effect of berberine on bile acid profile and gut microbiota in mice.
Guo Y; Zhang Y; Huang W; Selwyn FP; Klaassen CD
BMC Complement Altern Med; 2016 Oct; 16(1):394. PubMed ID: 27756364
[TBL] [Abstract][Full Text] [Related]
20. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.
Ma Y; Huang Y; Yan L; Gao M; Liu D
Pharm Res; 2013 May; 30(5):1447-57. PubMed ID: 23371517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
